Biotech drugmaker Human Genome Sciences Inc. is giving all bidders until July 16 to submit their final buyout offers and appealed to GlaxoSmithKline PLC to participate even though its prior bid was rejected.
The Rockville, Md.-based company said Friday that it is committed to exploring its strategic options.
Human Genome rejected the British pharmaceutical giant’s $13 per share offer last month, saying it was inadequate. At that time the company also adopted a “poison pill” shareholder rights plan in order to ward off any unsolicited takeover bids.
{iframe}http://www.cbsnews.com/8301-505245_162-57453801/human-genome-sets-deadline-for-buyout-offers/{/iframe}